Clinical Trials · NCT07840729
Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants
- Phase
- Phase 1
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Shanghai JMT-Bio Inc.
- Enrollment
- 90
- Start date
- Oct 2026
- Locations
- 1 site, China
- Primary endpoint
- Incidence of Adverse Events (AE) assessed by CTCAE v6.0